Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center.
Détails
Télécharger: Nature_s41541-020-00277-1.pdf (1304.43 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_F506D1AD4F8D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center.
Périodique
NPJ vaccines
ISSN
2059-0105 (Electronic)
ISSN-L
2059-0105
Statut éditorial
Publié
Date de publication
25/01/2021
Peer-reviewed
Oui
Volume
6
Numéro
1
Pages
15
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
The RV144 HIV-1 vaccine trial has been the only clinical trial to date that has shown any degree of efficacy and associated with the presence of vaccine-elicited HIV-1 envelope-specific binding antibody and CD4+ T-cell responses. This trial also showed that a vector-prime protein boost combined vaccine strategy was better than when used alone. Here we have studied three different priming vectors-plasmid DNA, recombinant MVA, and recombinant VSV, all encoding clade C transmitted/founder Env 1086 C gp140, for priming three groups of six non-human primates each, followed by a protein boost with adjuvanted 1086 C gp120 protein. Our data showed that MVA-priming favors the development of higher antibody binding titers and neutralizing activity compared with other vectors. Analyses of the draining lymph nodes revealed that MVA-prime induced increased germinal center reactivity characterized by higher frequencies of germinal center (PNA <sup>hi</sup> ) B cells, higher frequencies of antigen-specific B-cell responses as well as an increased frequency of the highly differentiated (ICOS <sup>hi</sup> CD150 <sup>lo</sup> ) Tfh-cell subset.
Pubmed
Web of science
Open Access
Oui
Création de la notice
27/01/2021 14:11
Dernière modification de la notice
16/09/2023 7:17